Salute e Benessere
YUTIQ Sees Continued Market Growth in Treatment of Chronic Non-Infectious Uveitis | DelveInsight
YUTIQ is a sterile, non-biodegradable intravitreal implant containing 0.18 mg of fluocinolone acetonide (FA). It provides a sustained drug release at an initial rate of 0.25 µg per day over 36 months. This corticosteroid-based therapy is indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The implant is preloaded in a single-use applicator for direct injection into the vitreous cavity. It received FDA approval in October 2018 and was commercially launched in the U.S. in February 2019 .
YUTIQ was developed to enhance the performance of RETISERT by delivering a lower corticosteroid dose to the retina, thereby reducing the incidence of adverse effects such as increased intraocular pressure (IOP) and cataract formation. Its extended duration of action also minimizes the need for frequent dosing, improving patient convenience and treatment tolerability.
Learn more about YUTIQ projected market size for uveitis @
Uveitis is a rare condition characterized by inflammation in part or all of the uvea, the middle layer of the eye that includes the choroid, ciliary body, and iris. This inflammation can also impact other parts of the eye, such as the lens, retina, optic nerve, and vitreous humor. Uveitis represents a broad spectrum of inflammatory eye disorders and may result from trauma, infections, tumors, or autoimmune and inflammatory diseases. According to DelveInsight, there were approximately diagnosed prevalent cases of uveitis across the 7MM in 2023, with numbers projected to rise between 2020 and 2034.
The primary objective of uveitis treatment is to control inflammation quickly, alleviate pain, and prevent vision loss and other complications. Current clinical guidelines stress the importance of early detection and timely intervention. Approved therapies include . The uveitis market in the 7MM was valued at around in 2023, and it is anticipated to grow further by 2034, driven by rising disease prevalence, enhanced understanding of its underlying mechanisms, and ongoing technological advancements.
Discover more about the uveitis market in detail @
Prominent players such as with TRS01, with OLUMIANT (baricitinib), with licaminlimab (OCS-02), with brepocitinib, and others are actively developing therapies for uveitis.
In was granted Fast Track Designation (FTD) for NIU by the FDA for the treatment of non-anterior NIU. Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
In received US FDA agreement under a Special Protocol Assessment (SPA) for the Phase III Tarsier-04 trial protocol and planned statistical analysis for evaluating TRS01 eye drops in treating non-infectious uveitis, including uveitic glaucoma.
To know more about the number of competing drugs in development, visit @
Discover how YUTIQ is shaping the uveitis treatment landscape @
YUTIQ, an intravitreal fluocinolone acetonide implant developed by EyePoint Pharmaceuticals, is designed for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The market dynamics for YUTIQ are shaped by several key factors, including the the , and as a sustained-release corticosteroid implant that provides up to three years of continuous drug delivery.
This , which often require more frequent injections and carry higher systemic side effect risks. These features have helped YUTIQ
, especially among ophthalmologists and retinal specialists managing patients with recurrent or refractory uveitis.
However, market penetration for YUTIQ also faces several headwinds. , particularly in markets where reimbursement is limited or slow to be adopted. The presence of competing therapies, such as , also affects uptake.
Furthermore, given the and the , growth is inherently capped by the size of the addressable market. Nonetheless, and with retina specialists continue to support gradual market expansion. Overall, while YUTIQ addresses a critical clinical need, its long-term commercial success will depend on navigating access challenges and differentiating further from both systemic and local therapies.
Dive deeper to get more insight into YUTIQ's strengths & weaknesses relative to competitors @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveitis companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key uveitis companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key autoimmune uveitis companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anterior uveitis companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/yutiq-sees-continued-market-growth-in-treatment-of-chronic-non-infectious-uveitis--delveinsight-302446752.html